Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
EAHP BOOST
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
European Council for Pharmacy Education Accreditation
Investigation of the hospital pharmacy profession in Europe
Hospital Pharmacy Day
SIGs
Controlled Substances Management
Special Interest Group on Investigation of medication errors and efficiency in oncology
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
2024 European Parliament Election Manifesto
Member Center
You are here
Home
Section 3: Production and Compounding
3PC-032
LOW-DOSE MORPHINE SOLUTION FOR SPINAL ANAESTHESIA - READY TO USE TO IMPROVE PATIENT SAFETY IN DRUG THERAPY
3PC-031
THE TRANSITION FROM THE USE OF BUPIVACAINE TO ROPIVACAINE IN THE DELIVERY ROOM, IN ORDER TO ACHIEVE A BETTER ANALGESIC EFFECT
3PC-030
PHYSICAL, CHEMICAL AND MICROBIOLOGICAL STABILITY OF SIROLIMUS 0.4% IN TOPICAL FORMULATIONS
3PC-029
QUALITY OF GEMCITABINE READY TO ADMINISTER PREPARATIONS
3PC-028
DOSE-BANDING GEMCITABINE AND STANDARDISATION OF CHEMOTHERAPY PROTOCOLS PRODUCTION
3PC-027
PRODUCTIVITY ANALYSIS OF AN AUTOMATED COMPOUNDING SYSTEM FOR INTRAVENOUS CHEMOTHERAPY
3PC-026
WHAT IS THE BEST CHEMICAL DECONTAMINATION SOLUTION FOR CONVENTIONAL ANTI-NEOPLASTIC DRUGS IN A HOSPITAL COMPOUNDING UNIT?
3PC-025
OPTIMISATION OF COMPOUNDING ORGANISATION AFTER IMPLEMENTING A ROBOTIC SYSTEM FOR AUTOMATED PREPARATION OF ONCOLOGIC DRUGS
3PC-024
THE VALIDATION OF CONTROL METHOD : THE GRAVIMETRIC ANALYSIS IN CYTOTOXIC DRUG PREPARATION
3PC-023
A RISK ANALYSIS METHOD TO EVALUATE THE IMPACT OF A CHEMOTHERAPY COMPOUNDING WORKFLOW MANAGEMENT SYSTEM ON CANCER PATIENTS' SAFETY
3PC-022
PRELIMINARY MICROBIOLOGICAL STUDY OF INJECTABLE CHEMOTHERAPY DOSE-BANDING
3PC-021
IMPACT OF A CENTRALISED INTRAVENOUS ADDITIVE SERVICE IN PATIENTS AND HEALTHCARE WORKERS RISK REDUCTION
3PC-020
NIVOLUMAB WEIGHT-BASED DOSING VS FLAT DOSE ECONOMIC ANALYSIS
3PC-019
RISK MANAGEMENT OF CROSS-CONTAMINATION OF PAEDIATRIC ANTI-CANCER PREPARATIONS USING FAILURE MODE AND EFFECTS CRITICALITY ANALYSIS
3PC-018
IMPLEMENTATION OF QUALITY CONTROL OF PAEDIATRIC CYTOTOXIC DRUG PREPARATIONS: PILOT TRIAL WITH ETOPOSIDE.
Pages
« first
‹ previous
…
11
12
13
14
15
16
17
18
19
next ›
last »
Follow Us